Beam Therapeutics Inc. cotiza a 25.13 USD y tiene una capitalización bursátil de $2.6B. En los últimos 12 meses ha facturado $156M con un margen de flujo de caja libre del -257.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-1.18 | $-0.91 | $2.33 |
| Estimado | $-1.17 | $-1.13 | $-1.01 | $-1.12 |
| Sorpresa | — | -4.4% | +9.9% | +308.0% |
| Métrica | BEAM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -274.6% | -38.6% | -235.9% |
| Net Margin | -57.2% | -33.6% | -23.7% |
| FCF Margin | -257.6% | -13.9% | -243.8% |
| ROE | -6.5% | -40.4% | +33.9% |
| ROA | -5.4% | -32.0% | +26.6% |
| Current Ratio | 13.09 | 2.84 | +10.25 |
| Debt / Equity | — | 0.28 | — |